EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC (PRECENT)

Jianxing He

Status: Unknown

Conditions: Nonsmall Cell Lung Cancer

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT02988141

CCTC1601

Details and patient eligibility

About

A Prospective Multi-center Study to Investigate the EGFR-TKI Resistance Profile in Chinese Patients with Advanced EGFRm+ NSCLC

Full description

Patients with EGFR mutation and presented secondary resistance to prior first-generation EGFR-TKI should have received biopsy of at least on progressed lesions and are able to provide tissues for pathological examination and NGS testing.All enrolled patients will be followed up to clinical outcome (treatments, tumor response, survival, etc).

Enrollment: 100 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Provision of informed consent prior to any study specific procedures.
• Male or female patients aged 18 years and older.
• Histological confirmation of stage IIIB/IV NSCLC.
• Documented EGFR mutation positive .
• WHO Performance Status 0, 1 or 2

Exclusion criteria

• Any other significant clinical disorder or laboratory finding that made it undesirable for the patient to participate in the study.
• Previous (within 6 months) or current treatment with AZD9291.